Spondyloarthritis & psoriatic arthritis
Risk of Spondyloarthritis in Patients With Inflammatory Bowel Disease Receiving Treatment With Biologics or Janus Kinase Inhibitors
Authors' conclusion
During a median follow-up of 5.2 years, 6.8% of patients with IBD undergoing biologic or JAKi treatment developed MSK symptoms, with one-third subsequently diagnosed with SpA. HLA-B27 positivity and higher UC disease activity were associated with an increased risk of SpA.
Study context
- Population
- Patients with inflammatory bowel disease (IBD) receiving biologics or Janus kinase inhibitor (JAKi), excluding prior spondyloarthritis (SpA)1,553 analysed
- Participants
- 1,649 patients
- Outcome
- SpA diagnosed by a rheumatologist (clinical evaluation, radiographs, HLA-B27; sacroiliac MRI if radiograph inconclusive) during IBD treatment
Main finding
As reported in the abstract
SpA diagnosis · median 5.2 [IQR 3.4-7.5] years
Diagnosed with SpA
30
1.9%
Axial SpA
20
Peripheral SpA
10
Developed musculoskeletal (MSK) symptoms during IBD treatment
106
6.8%
Observational data: associations, not effects.
Further findings
Risk factors for SpA
| HR | P value | |
|---|---|---|
| Partial Mayo score for UC at onset of MSK symptoms | 1.57 | P = 0.03 |
| HLA-B27 positivity | 3.70 | P = 0.004 |
NSAID use among patients with SpA
- Used nonsteroidal antiinflammatory drugs (NSAIDs) as well as IBD treatment
- 23/30 (77%)
Safety
IBD disease activity
- Did not worsen during treatment, regardless of NSAID use
Original publication
Risk of Spondyloarthritis in Patients With Inflammatory Bowel Disease Receiving Treatment With Biologics or Janus Kinase Inhibitors. J Rheumatol. Published 25 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →